Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
91.13 EUR | +0.13% | +1.53% | +1.53% |
Jun. 06 | Ipsen Hires New Chief Corporate Affairs Officer | MT |
Jun. 05 | Lupin Arm Acquires Two Brands from Sanofi in Europe and Canada | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the best yield companies with high dividend expectations.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.53% | 123B | B+ | ||
+45.82% | 765B | C+ | ||
-6.16% | 354B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.45% | 248B | B+ | ||
-0.78% | 219B | A+ | ||
+11.88% | 216B | B- | ||
+5.90% | 164B | C+ | ||
-0.73% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SAN Stock
- Ratings Sanofi